279.95
+5.70%
Close of 9 Nov 2026, in INR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Suven Life Sciences
Its shares trade on NSE under the ticker SUVEN.NS. It has been listed since 6 March 1995. In the fiscal year to 31 March 2026, it reported revenue of ₹71.1m and a net loss of ₹2.76bn. At that date it held total assets of ₹6.24bn and shareholders' equity of ₹5.91bn.
Suven Life Sciences Ltd. engages on discovering, developing, and commercializing novel pharmaceutical products which are used in classic therapies. The company is headquartered in Hyderabad, Telangana. The firm is engaged in the drug discovery and development of new chemical entities (NCEs) in central nervous system (CNS) disorders targeting unmet medical needs, globally. The company operates through the research and development services segment. Its drug discovery & research/clinical pipeline include Masupirdine (SUVN-502) Neuropsychiatric Symptoms in Alzheimer's, Masupirdine (SUVN-502) Cognitive deficits in AD, Samelisant (SUVN-G3031) Narcolepsy, Samelisant (SUVN-G3031) Cognitive Disorders, Ropanicant (SUVN-911) Depressive Disorders, Usmarapride (SUVN-D4010), Cognitive Disorders, SUVN-I6107, Cognitive Disorders and Schizophrenia, SUVN-M8036, Psychiatric Disorders, and SUVN-D1044 Gastrointestinal Disorders. Its drug discovery & development support services (DDDSS) include synthetic and medicinal chemistry, analytical chemistry, in vitro biology, ADME, pharmacology, toxicology, bioanalysis, and NCE formulations.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Life Sciences Tools & Services
- Listed since
- 6 Mar 1995
- Employees
- 132
- Website
- suven.com ↗
Leadership
Pay as last reported
- Mr. Venkateswarlu JastiExecutive Chairman of the Board, Managing Director, since 2024₹58.3m
- Mr. M. Mohan KumarChief Financial Officer
- Ms. Sangeetha KandariCompany Secretary and Compliance Officer
- Smt. Sudha JastiWholetime Director₹22.8m
- Prof. Dr. Syed HasnainNon-Executive Director₹260,000
- Mr. Santanu MukherjeeIndependent Non-Executive Director₹310,000
- Smt. J.A.S PadmajaNon-Executive Independent Director₹250,000
- Mr. Vajja RaoAdditional Non-Executive Independent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Suven Life Sciences Ltd. focuses on CNS disorders with 8 pipeline products targeting unmet medical needs.
- The company employs 132 full-time employees specializing in drug discovery and development services.
- Hyderabad headquarters supports operations in the Health Care sector with a strong R&D focus.
Weaknesses
- The company has a limited number of 132 employees for a global drug discovery focus.
- Only 8 pipeline products are listed without detailed commercialization timelines.
- No mention of international partnerships or collaborations in the provided facts.
Opportunities
- Expanding the CNS drug pipeline to address Alzheimer's and narcolepsy with SUVN-502 and SUVN-G3031.
- Growing demand for psychiatric disorder treatments in the global Health Care sector.
- Increasing focus on cognitive disorders with multiple products like SUVN-I6107 and SUVN-D4010.
Threats
- Competition in CNS drug discovery from larger pharmaceutical companies globally.
- Regulatory challenges in developing new chemical entities for psychiatric disorders.
- Dependency on a narrow focus in CNS disorders without diversification into other sectors.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.